Publications by authors named "Natalia Rompoti"

Claim this Profile
E
Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.
Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in psoriasis patients: results from a real-world multicentre study.
Alexander Katoulis, Evangelia Papadavid, Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki

Clin Exp Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.
Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Natalia Rompoti, Charitomeni Vavouli, Maria Politou

Int J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study.
Tiago Torres, Jensen Yeung, Vimal Prajapati, Simone Ribero, Anna Balato, Natalia Rompoti

J Eur Acad Dermatol Venereol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.
Tiago Torres, Jensen Yeung, Vimal H Prajapati, Simone Ribero, Anna Balato, Natalia Rompoti

Dermatol Ther (Heidelb)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of second primary cancers in patients with Merkel cell carcinoma: A systematic review and meta-analysis.
Ioannis-Alexios Koumprentziotis, Aikaterini Tsiogka, Natalia Rompoti, Stergios Soulaidopoulos, Vasiliki Nikolaou

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.
Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki, Charitomeni Vavouli, Maria Politou

Int J Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.
Irene Stefanaki, Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Pantelis Panagakis, Charitomeni Vavouli

Int J Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.
Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki, Charitomeni Vavouli, Marina Papoutsaki

Australas J Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severity.
Nikolaos Rotsiamis, Natalia Rompoti, Aikaterini Liakou, Andreas G Tsantes, Stefanos Bonovas

Arch Dermatol Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Natalia Rompoti, Irene Stefanaki, Pantelis Panagakis, Marina Papoutsaki, Maria Politou

J Eur Acad Dermatol Venereol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Andrea Chiricozzi, Giulia Coscarella, Luis Puig, Ron Vender, Jensen Yeung, Natalia Rompoti

J Eur Acad Dermatol Venereol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.
Natalia Rompoti, Theognosia Vergou, Irene Stefanaki, Charitomeni Vavouli, Ioannis-Alexios Koumprentziotis

Int J Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.
Natalia Rompoti, Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Charitomeni Vavouli, Marina Papoutsaki

Arch Dermatol Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychopathological Profile of Patients with Moderate-to-Severe Plaque Psoriasis and Its Correlation to DLQI: Results from a Prospective, Monocentric Clinical Study.
Natalia Rompoti, Sofia Tsiori, Konstantinos Kontoangelos, Anastasios Kouzoupis, Charalabos Papageorgiou

J Clin Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Inflammatory Markers and Psychometric Scores in Patients with Hidradenitis Suppurativa.
Aikaterini I Liakou, Nikolaos Rotsiamis, Andreas G Tsantes, Eleni Routsi, Natalia Rompoti

J Clin Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
Natalia Rompoti, Irene Stefanaki, Pantelis Panagakis, Charitomeni Vavouli, Maria Politou

Arch Dermatol Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photodynamic Therapy for the Treatment of Basal Cell Carcinoma: A Comprehensive Review of Randomized Controlled Trials.
Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Konstantinos Liopyris, Electra Nicolaidou, Alexander Stratigos

Dermatol Pract Concept· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
Tiago Torres, Andrea Chiricozzi, Luis Puig, Ana Maria Lé, Angelo Valerio Marzano, Natalia Rompoti

Am J Clin Dermatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
Natalia Rompoti, Maria Politou, Irene Stefanaki, Charitomeni Vavouli, Marina Papoutsaki

J Eur Acad Dermatol Venereol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.
Aikaterini Tsiogka, Stamatios Gregoriou, Alexander Stratigos, Stergios Soulaidopoulos, Natalia Rompoti

Biomedicines· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Tiago Torres, Luis Puig, Ron Vender, Jensen Yeung, José-Manuel Carrascosa, Natalia Rompoti

Am J Clin Dermatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychopathology and Alexithymia in Patients with Moderate-to-Severe Psoriasis: Development of a Novel Index with Prognostic Value.
Sofia Tsiori, Natalia Rompoti, Konstantinos Kontoangelos, Christos Papageorgiou, Charalabos Papageorgiou

Int J Environ Res Public Health· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Nail Psoriasis.
Dimitrios Rigopoulos, Natalia Rompoti, Stamatios Gregoriou

Dermatol Clin· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
Natalia Rompoti, Pelagia Katsimbri, Georgios Kokkalis, Dimitrios Boumpas, Ignatios Ikonomidis

Dermatol Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis